Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies

Annals of Diagnostic Pathology

Volumn 25, Issue , 2016, Pages 64-71

  Thway, Khin ^a   Noujaim, Jonathan ^a   Jones, Robin L ^a   Fisher, Cyril ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bedn tumor; COL1A1 PDGFB; Dermatofibrosarcoma protuberans; Fibrosarcoma; Giant cell fibroblastoma; Sarcoma; Translocation

Indexed keywords

CD34 ANTIGEN; IMATINIB; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMOSURGERY; CLINICAL FEATURE; COL1A1 PDGFB FUSION GENE; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; FUSION GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; MOLECULAR GENETICS; PRIORITY JOURNAL; SPINDLE CELL; SYSTEMIC THERAPY; TREATMENT INDICATION; DERMATOFIBROSARCOMA; GENE TRANSLOCATION; GENETICS; MOLECULAR PATHOLOGY; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; DERMATOFIBROSARCOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY, MOLECULAR; SKIN NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 84990903073     PISSN: 10929134     EISSN: 15328198     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2016.09.013     Document Type: Article

References (99)

1. [1] Dominguez-Malagon, H., Valdez-Carrillo Mdel, C., Cano-Valdez, A.M., Dermatofibroma and dermatofibrosarcoma protuberans: a comparative ultrastructural study. Ultrastruct Pathol 30 (2006), 283–291.
2. [2] Zina, A.M., Bundino, S., Dermatofibrosarcoma protuberans. An ultrastructural study of five cases. J Cutan Pathol 6 (1979), 265–271.
3. [3] Criscione, V.D., Weinstock, M.A., Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 56 (2007), 968–973.
4. [4] Valdivielso-Ramos, M., Hernanz, J.M., Dermatofibrosarcoma protuberans in childhood. Actas Dermosifiliogr 103 (2012), 863–873.
5. [5] Terrier-Lacombe, M.J., Guillou, L., Maire, G., Terrier, P., Vince, D.R., de Saint Aubain Somerhausen, N., et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data—a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 27 (2003), 27–39.
6. [6] Noujaim, J., Thway, K., Fisher, C., Jones, R.L., Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biol Med 12 (2015), 375–384.
7. [7] Maire, G., Fraitag, S., Galmiche, L., Keslair, F., Ebran, N., Terrier-Lacombe, M.J., et al. A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol 143 (2007), 203–210.
8. [8] Connelly, J.H., Evans, H.L., Dermatofibrosarcoma protuberans. A clinicopathologic review with emphasis on fibrosarcomatous areas. Am J Surg Pathol 16 (1992), 921–925.
9. [9] Bowne, W.B., Antonescu, C.R., Leung, D.H., Katz, S.C., Hawkins, W.G., Woodruff, J.M., et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 88 (2000), 2711–2720.
10. [10] Rutgers, E.J., Kroon, B.B., Albus-Lutter, C.E., Gortzak, E., Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 18 (1992), 241–248.
11. [11] Chang, C.K., Jacobs, I.A., Salti, G.I., Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 30 (2004), 341–345.
12. [12] Gloster, H.M. Jr., Dermatofibrosarcoma protuberans. J Am Acad Dermatol 35 (1996), 355–374 [quiz 75–6].
13. [13] Garcia, J.J., Folpe, A.L., The impact of advances in molecular genetic pathology on the classification, diagnosis and treatment of selected soft tissue tumors of the head and neck. Head Neck Pathol 4 (2010), 70–76.
14. [14] Edelweiss, M., Malpica, A., Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases. Am J Surg Pathol 34 (2010), 393–400.
15. [15] Bague, S., Folpe, A.L., Dermatofibrosarcoma protuberans presenting as a subcutaneous mass: a clinicopathological study of 15 cases with exclusive or near-exclusive subcutaneous involvement. Am J Dermatopathol 30 (2008), 327–332.
16. [16] King, L., Lopez-Terrada, D., Jakacky, J., McCarville, M.B., Spunt, S.L., Bridge, J.A., et al. Primary intrathoracic dermatofibrosarcoma protuberans. Am J Surg Pathol 36 (2012), 1897–1902.
17. [17] Laskin, W.B., Dermatofibrosarcoma protuberans. CA Cancer J Clin 42 (1992), 116–125.
18. [18] Rockley, P.F., Robinson, J.K., Magid, M., Goldblatt, D., Dermatofibrosarcoma protuberans of the scalp: a series of cases. J Am Acad Dermatol 21 (1989), 278–283.
19. [19] Wrotnowski, U., Cooper, P.H., Shmookler, B.M., Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am J Surg Pathol 12 (1988), 287–293.
20. [20] Zhang, L., Liu, Q.Y., Cao, Y., Zhong, J.S., Zhang, W.D., Dermatofibrosarcoma protuberans: computed tomography and magnetic resonance imaging findings. Medicine (Baltimore), 94, 2015, e1001.
21. [21] Fiore, M., Miceli, R., Mussi, C., Lo Vullo, S., Mariani, L., Lozza, L., et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 23 (2005), 7669–7675.
22. [22] Corey, R.M., Swett, K., Ward, W.G., Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med 3 (2014), 1404–1415.
23. [23] Khatri, V.P., Galante, J.M., Bold, R.J., Schneider, P.D., Ramsamooj, R., Goodnight, J.E. Jr., Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol 10 (2003), 1118–1122.
24. [24] Abbott, J.J., Oliveira, A.M., Nascimento, A.G., The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol 30 (2006), 436–443.
25. [25] Goldblum, J.R., Reith, J.D., Weiss, S.W., Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol 24 (2000), 1125–1130.
26. [26] Rutkowski, P., Debiec-Rychter, M., Current treatment options for dermatofibrosarcoma protuberans. Expert Rev Anticancer Ther 15 (2015), 901–909.
27. [27] Sjoblom, T., Shimizu, A., O'Brien, K.P., Pietras, K., Dal Cin, P., Buchdunger, E., et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61 (2001), 5778–5783.
28. [28] Greco, A., Roccato, E., Miranda, C., Cleris, L., Formelli, F., Pierotti, M.A., Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 92 (2001), 354–360.
29. [29] Maki, R.G., Awan, R.A., Dixon, R.H., Jhanwar, S., Antonescu, C.R., Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100 (2002), 623–626.
30. [30] Rubin, B.P., Schuetze, S.M., Eary, J.F., Norwood, T.H., Mirza, S., Conrad, E.U., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20 (2002), 3586–3591.
31. [31] Ugurel, S., Mentzel, T., Utikal, J., Helmbold, P., Mohr, P., Pfohler, C., et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res 20 (2014), 499–510.
32. [32] Kerob, D., Porcher, R., Verola, O., Dalle, S., Maubec, E., Aubin, F., et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 16 (2010), 3288–3295.
33. [33] McArthur, G.A., Demetri, G.D., van Oosterom, A., Heinrich, M.C., Debiec-Rychter, M., Corless, C.L., et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23 (2005), 866–873.
34. [34] Rutkowski, P., Van Glabbeke, M., Rankin, C.J., Ruka, W., Rubin, B.P., Debiec-Rychter, M., et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 28 (2010), 1772–1779.
35. [35] Fu, Y., Kang, H., Zhao, H., Hu, J., Zhang, H., Li, X., et al. Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib. Int J Clin Exp Med 8 (2015), 8288–8294.
36. [36] Kamar, F.G., Kairouz, V.F., Sabri, A.N., Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clin Sarcoma Res, 3, 2013, 5.
37. [37] Rutkowski, P., Debiec-Rychter, M., Nowecki, Z., Michej, W., Symonides, M., Ptaszynski, K., et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 25 (2011), 264–270.
38. [38] Rutkowski, P., Wozniak, A., Switaj, T., Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma, 2011, 2011, 959132.
39. [39] Labropoulos, S.V., Fletcher, J.A., Oliveira, A.M., Papadopoulos, S., Razis, E.D., Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 16 (2005), 461–466.
40. [40] Sirvent, N., Maire, G., Pedeutour, F., Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 37 (2003), 1–19.
41. [41] Fisher, C., Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. Virchows Arch 456 (2010), 153–166.
42. [42] Abbott, J.J., Erickson-Johnson, M., Wang, X., Nascimento, A.G., Oliveira, A.M., Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol 19 (2006), 1512–1518.
43. [43] Sonobe, H., Furihata, M., Iwata, J., Ohtsuki, Y., Chikazawa, M., Taguchi, T., et al. Dermatofibrosarcoma protuberans harboring t(9;22)(q32;q12.2). Cancer Genet Cytogenet 110 (1999), 14–18.
44. [44] Patel, K.U., Szabo, S.S., Hernandez, V.S., Prieto, V.G., Abruzzo, L.V., Lazar, A.J., et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 39 (2008), 184–193.
45. [45] Maire, G., Martin, L., Michalak-Provost, S., Gattas, G.J., Turc-Carel, C., Lorette, G., et al. Fusion of COL1A1 exon 29 with PDGFB exon 2 in a der(22)t(17;22) in a pediatric giant cell fibroblastoma with a pigmented Bednar tumor component. Evidence for age-related chromosomal pattern in dermatofibrosarcoma protuberans and related tumors. Cancer Genet Cytogenet 134 (2002), 156–161.
46. [46] Greco, A., Fusetti, L., Villa, R., Sozzi, G., Minoletti, F., Mauri, P., et al. Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 17 (1998), 1313–1319.
47. [47] Shimizu, A., O'Brien, K.P., Sjoblom, T., Pietras, K., Buchdunger, E., Collins, V.P., et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 59 (1999), 3719–3723.
48. [48] Takahira, T., Oda, Y., Tamiya, S., Higaki, K., Yamamoto, H., Kobayashi, C., et al. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Mod Pathol 20 (2007), 668–675.
49. [49] Heldin, C.H., Westermark, B., Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79 (1999), 1283–1316.
50. [50] Andrae, J., Gallini, R., Betsholtz, C., Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22 (2008), 1276–1312.
51. [51] Ha, S.Y., Lee, S.E., Kwon, M.J., Kim, Y.J., Lee, E.H., Seo, J., et al. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications. Hum Pathol 44 (2013), 1300–1309.
52. [52] Segura, S., Salgado, R., Toll, A., Martin-Ezquerra, G., Yebenes, M., Saez, A., et al. Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays. Hum Pathol 42 (2011), 176–184.
53. [53] Kerob, D., Pedeutour, F., Leboeuf, C., Verola, O., de Kerviler, E., Servant, J.M., et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 26 (2008), 1757–1759.
54. [54] Salgado, R., Llombart, B., MP, R., Fernandez-Serra, A., Sanmartin, O., Toll, A., et al. Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase–polymerase chain reaction and fluorescence in situ hybridization methodologies. Genes Chromosomes Cancer 50 (2011), 510–517.
55. [55] Kiuru-Kuhlefelt, S., El-Rifai, W., Fanburg-Smith, J., Kere, J., Miettinen, M., Knuutila, S., Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. Cytogenet Cell Genet 92 (2001), 192–195.
56. [56] Takahira, T., Oda, Y., Tamiya, S., Yamamoto, H., Kawaguchi, K., Kobayashi, C., et al. Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. Hum Pathol 35 (2004), 240–245.
57. [57] Sandberg, A.A., Bridge, J.A., Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 140 (2003), 1–12.
58. [58] Linn, S.C., West, R.B., Pollack, J.R., Zhu, S., Hernandez-Boussard, T., Nielsen, T.O., et al. Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Surg Pathol 163 (2003), 2383–2395.
59. [59] Lin, N., Urabe, K., Moroi, Y., Uchi, H., Nakahara, T., Dainichi, T., et al. Overexpression of phosphorylated-STAT3 and phosphorylated-ERK protein in dermatofibrosarcoma protuberans. Eur J Dermatol 16 (2006), 262–265.
60. [60] Maekawa, T., Jinnin, M., Ohtsuki, M., Ihn, H., The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans. Eur J Dermatol 21 (2011), 534–538.
61. [61] Kajihara, I., Jinnin, M., Harada, M., Makino, K., Honda, N., Makino, T., et al. miR-205 down-regulation promotes proliferation of dermatofibrosarcoma protuberans tumor cells by regulating LRP-1 and ERK phosphorylation. Arch Dermatol Res 306 (2014), 367–374.
62. [62] Bianchini, L., Maire, G., Guillot, B., Joujoux, J.M., Follana, P., Simon, M.P., et al. Complex t(5;8) involving the CSPG2 and PTK2B genes in a case of dermatofibrosarcoma protuberans without the COL1A1-PDGFB fusion. Virchows Arch 452 (2008), 689–696.
63. [63] Calonje, E., Fletcher, C.D., Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant: clinicopathologic analysis of 5 cases. J Cutan Pathol 23 (1996), 30–36.
64. [64] Sanz-Trelles, A., Myoid cells in the fibrosarcomatous variant of dermatofibrosarcoma protuberans. Are they neoplastic?. Histopathology 34 (1999), 179–180.
65. [65] Mentzel, T., Scharer, L., Kazakov, D.V., Michal, M., Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol 29 (2007), 443–448.
66. [66] Frierson, H.F., Cooper, P.H., Myxoid variant of dermatofibrosarcoma protuberans. Am J Surg Pathol 7 (1983), 445–450.
67. [67] Reimann, J.D., Fletcher, C.D., Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases. Am J Surg Pathol 31 (2007), 1371–1377.
68. [68] Fletcher, C.D., Theaker, J.M., Flanagan, A., Krausz, T., Pigmented dermatofibrosarcoma protuberans (Bednar tumour): melanocytic colonization or neuroectodermal differentiation? A clinicopathological and immunohistochemical study. Histopathology 13 (1988), 631–643.
69. [69] Nishio, J., Iwasaki, H., Ishiguro, M., Ohjimi, Y., Yo, S., Isayama, T., et al. Supernumerary ring chromosome in a Bednar tumor (pigmented dermatofibrosarcoma protuberans) is composed of interspersed sequences from chromosomes 17 and 22: a fluorescence in situ hybridization and comparative genomic hybridization analysis. Genes Chromosomes Cancer 30 (2001), 305–309.
70. [70] Shmookler, B.M., Enzinger, F.M., Weiss, S.W., Giant cell fibroblastoma. A juvenile form of dermatofibrosarcoma protuberans. Cancer 64 (1989), 2154–2161.
71. [71] Billings, S.D., Folpe, A.L., Cutaneous and subcutaneous fibrohistiocytic tumors of intermediate malignancy: an update. Am J Dermatopathol 26 (2004), 141–155.
72. [72] Jha, P., Moosavi, C., Fanburg-Smith, J.C., Giant cell fibroblastoma: an update and addition of 86 new cases from the armed forces Institute of Pathology, in honor of Dr. Franz M. Enzinger. Ann Diagn Pathol 11 (2007), 81–88.
73. [73] Maire, G., Pedeutour, F., Coindre, J.M., COL1A1-PDGFB gene fusion demonstrates a common histogenetic origin for dermatofibrosarcoma protuberans and its granular cell variant. Am J Surg Pathol 26 (2002), 932–937.
74. [74] Banerjee, S.S., Harris, M., Eyden, B.P., Hamid, B.N., Granular cell variant of dermatofibrosarcoma protuberans. Histopathology 17 (1990), 375–378.
75. [75] Zelger, B.W., Ofner, D., Zelger, B.G., Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans. Histopathology 26 (1995), 519–527.
76. [76] Llatjos, R., Fernandez-Figueras, M.T., Diaz-Cascajo, C., Ribera, M., Ariza, A., Palisading and verocay body-prominent dermatofibrosarcoma protuberans: a report of three cases. Histopathology 37 (2000), 452–455.
77. [77] Tantcheva-Poor, I., Marathovouniotis, N., Kutzner, H., Mentzel, T., Vascular congenital dermatofibrosarcoma protuberans: a new histological variant of dermatofibrosarcoma protuberans. Am J Dermatopathol 34 (2012), e46–e49.
78. [78] Mentzel, T., Beham, A., Katenkamp, D., Dei Tos, A.P., Fletcher, C.D., Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 22 (1998), 576–587.
79. [79] Goldblum, J.R., CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans. Arch Pathol Lab Med 119 (1995), 238–241.
80. [80] Sheng, W.Q., Hashimoto, H., Okamoto, S., Ishida, T., Meis-Kindblom, J.M., Kindblom, L.G., et al. Expression of COL1A1-PDGFB fusion transcripts in superficial adult fibrosarcoma suggests a close relationship to dermatofibrosarcoma protuberans. J Pathol 194 (2001), 88–94.
81. [81] Bandarchi, B., Ma, L., Marginean, C., Hafezi, S., Zubovits, J., Rasty, G., D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans. Mod Pathol 23 (2010), 434–438.
82. [82] Lisovsky, M., Hoang, M.P., Dresser, K.A., Kapur, P., Bhawan, J., Mahalingam, M., Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Mod Pathol 21 (2008), 31–38.
83. [83] West, R.B., Harvell, J., Linn, S.C., Liu, C.L., Prapong, W., Hernandez-Boussard, T., et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 28 (2004), 1063–1069.
84. [84] Calonje, E., Mentzel, T., Fletcher, C.D., Cellular benign fibrous histiocytoma. Clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. Am J Surg Pathol 18 (1994), 668–676.
85. [85] Vivero, M., Doyle, L.A., Fletcher, C.D., Mertens, F., Hornick, J.L., GRIA2 is a novel diagnostic marker for solitary fibrous tumour identified through gene expression profiling. Histopathology 65 (2014), 71–80.
86. [86] Thway, K., Ng, W., Noujaim, J., Jones, R.L., Fisher, C., The current status of solitary fibrous tumor: diagnostic features, variants, and genetics. Int J Surg Pathol 24 (2016), 281–292.
87. [87] Doyle, L.A., Vivero, M., Fletcher, C.D., Mertens, F., Hornick, J.L., Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol 27 (2014), 390–395.
88. [88] Yoshida, A., Tsuta, K., Ohno, M., Yoshida, M., Narita, Y., Kawai, A., et al. STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol 38 (2014), 552–559.
89. [89] Cheah, A.L., Billings, S.D., Goldblum, J.R., Carver, P., Tanas, M.Z., Rubin, B.P., STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics. Pathology 46 (2014), 389–395.
90. [90] Chen, B.J., Marino-Enriquez, A., Fletcher, C.D., Hornick, J.L., Loss of retinoblastoma protein expression in spindle cell/pleomorphic lipomas and cytogenetically related tumors: an immunohistochemical study with diagnostic implications. Am J Surg Pathol 36 (2012), 1119–1128.
91. [91] Folpe, A.L., Billings, S.D., McKenney, J.K., Walsh, S.V., Nusrat, A., Weiss, S.W., Expression of claudin-1, a recently described tight junction-associated protein, distinguishes soft tissue perineurioma from potential mimics. Am J Surg Pathol 26 (2002), 1620–1626.
92. [92] Ahrens, W.A., Ridenour, R.V. III, Caron, B.L., Miller, D.V., Folpe, A.L., GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol 39 (2008), 1519–1526.
93. [93] Thway, K., Fisher, C., Malignant peripheral nerve sheath tumor: pathology and genetics. Ann Diagn Pathol 18 (2014), 109–116.
94. [94] Terry, J., Saito, T., Subramanian, S., Ruttan, C., Antonescu, C.R., Goldblum, J.R., et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 31 (2007), 240–246.
95. [95] Kosemehmetoglu, K., Vrana, J.A., Folpe, A.L., TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol 22 (2009), 872–878.
96. [96] Thway, K., Fisher, C., Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol 18 (2014), 369–380.
97. [97] Fisher, C., Synovial sarcoma. Ann Diagn Pathol 2 (1998), 401–421.
98. [98] Ng, W., Lee, J., Vroobel, K., Thway, K., DOG1 expression in soft tissue tumors. Int J Surg Pathol 24 (2016), 274–276.
99. [99] Novelli, M., Rossi, S., Rodriguez-Justo, M., Taniere, P., Seddon, B., Toffolatti, L., et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 57 (2010), 259–270.